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Abstract 22 
Objective  23 
To compare the diagnostic effectiveness of selective versus universal ultrasonography as a 24 
screening test for large for gestational age (LGA) infants, and to determine whether 25 
previously described ultrasonic markers of excessive fetal growth could identify which 26 
suspected LGA fetuses were at increased risk of neonatal morbidity.  27 
Methods 28 
We analysed data from a prospective cohort study of nulliparous women, the Pregnancy 29 
Outcome Prediction study. All women had clinically indicated scans as per routine care. 30 
Additionally, all women had blinded ultrasonic estimated fetal weight (EFW) performed at 31 
around 36 weeks of gestational age (wkGA). Screen positive for LGA was defined as an 32 
EFW >90th percentile ≥34wkGA.  33 
Results 34 
The current analysis included 3,866 eligible women. Of these, 177 (5%) infants had a birth 35 
weight >90th percentile. 1,354 (35%) women had a clinically indicated ultrasonography 36 
≥34wkGA. The sensitivity of selective ultrasonography was 27% and the sensitivity of 37 
universal ultrasonography was 38%. The specificity of both approaches was high (99% and 38 
97%, respectively). Using universal ultrasonography, neonatal outcome differed (P for 39 
interaction) by abdominal circumference growth velocity (ACGV) for both any neonatal 40 
morbidity (P=0.08) and severe adverse neonatal outcome (P=0.03). LGA fetuses with 41 
increased ACGV had a relative risk (95% CI, P) of any neonatal morbidity of 2.0 (1.1-3.6, 42 
P=0.04) and severe adverse neonatal outcome of 6.5 (2.0-21.1, P=0.01), whereas LGA 43 
fetuses with normal ACGV were not at increased risk.  44 
Conclusion 45 
Screening using universal ultrasonographic fetal biometry increases the detection of LGA 46 
infants and combined with ACGV identifies infants at increased risk of adverse neonatal 47 
outcome.   48 




A large for gestational age (LGA) infant is defined as one with birthweight higher than the 51 
90th percentile for the given week of pregnancy. LGA infants are at higher risk of morbidity, 52 
including shoulder dystocia and brachial plexus injury,(1) as well as mortality including both 53 
antepartum stillbirth and delivery related perinatal death.(2) Ultrasonic fetal biometry can be 54 
used as a means to identify suspected LGA fetuses. The two obvious candidate 55 
interventions following this diagnosis are planned caesarean delivery, which may prevent the 56 
risk of birth injury, and early induction of labor, which may reduce birth weight by 57 
abbreviating the duration of pregnancy. A cost-benefit analysis indicated that caesarean 58 
delivery for non-diabetic women with suspected macrosomia is not justified.(3) Until recently, 59 
there has been no direct evidence for a beneficial effect of induction of labor.(4) However, an 60 
RCT published in 2015 suggested that early induction of labor (between 37+0 to 38+6 61 
weeks’ gestation) for ultrasonically suspected LGA reduced a composite of shoulder 62 
dystocia and perinatal morbidity by about 70% without increasing the risk of caesarean 63 
section.(5) 64 
 65 
Currently, clinical guidelines in the UK(6) and the US(7) recommend that women should not 66 
be routinely screened using ultrasound in the last third of pregnancy, as there is no clear 67 
evidence of benefit from a meta-analysis of randomized controlled trials (RCTs),(8) and false 68 
positive ultrasonic diagnoses have the potential to cause harm through unnecessary 69 
intervention. However, the UK Guideline recommended further research on the diagnostic 70 
effectiveness of universal ultrasound. We undertook a prospective cohort study between 71 
2008 and 2013, with a design to generate Level 1 evidence of the diagnostic effectiveness of 72 
universal serial ultrasound, i.e. where the results were blinded to the women and their 73 
carers. We have previously reported our results on screening for fetal growth restriction.(9) 74 
The aims of the present study were: 1. to compare the diagnostic effectiveness of selective 75 
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versus universal ultrasound as a screening test for LGA. 2. to determine which, if any, of a 76 
series of previously described ultrasonic markers of excessive fetal growth could identify 77 
LGA infants which were at increased risk of adverse neonatal outcome.  78 




Study design 81 
The Pregnancy Outcome Prediction study was a prospective cohort study conducted at the 82 
Rosie Hospital, Cambridge (UK) and has previously been described in detail.(9, 10) In brief, 83 
nulliparous women attending for their dating ultrasound scan between 14/01/2008 and 84 
31/07/2012 with a viable singleton pregnancy were eligible. Women who agreed to 85 
participate signed a consent form and were given follow up appointments at approximately 86 
20, 28 and 36 weeks gestational age (wkGA) in the NIHR Cambridge Clinical Research 87 
Facility. Women were selected for clinically indicated ultrasound scans in the third trimester 88 
as per routine clinical care using local and national guidelines, and the results of these scans 89 
were reported (selective ultrasonography). In contrast, women and clinicians were blinded to 90 
the results of the research ultrasound scans (universal ultrasonography). The study was 91 
designed to generate level 1 evidence of diagnostic effectiveness, as defined by the UK’s 92 
National Institute for Health and Care Excellence (NICE).(11) The reporting of this study 93 
conforms to the STARD (Standards for Reporting Diagnostic accuracy studies) 94 
guidelines.(12) Ethical approval for the study was given by the Cambridgeshire 2 Research 95 
Ethics Committee (reference number 07/H0308/163). The inclusion criteria for the present 96 
analysis were that women attended their 36 week research scan and had a live birth at the 97 
Rosie Hospital. Women who delivered prior to their 36 week scan appointment were 98 
excluded. 99 
 100 
Selective and universal ultrasonography 101 
The results of clinically indicated scans was ascertained by linkage of the research data to 102 
the hospital’s electronic ultrasonography database (Astraia, Munich, Germany). In both 103 
selective (clinically indicated) and universal (research) ultrasonography, fetal biometry 104 
included measurement of fetal biparietal diameter, head circumference (HC), abdominal 105 
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circumference (AC) and femur length (FL) using standard techniques. An estimated fetal 106 
weight (EFW) percentile was calculated using the Hadlock equations and reference 107 
standard.(13, 14) Where all four measurements were available, the formula employing all 108 
measurements was used: EFW = 10(1.3596 - 0.00386*AC*FL + 0.0064*HC + 0.00061*BPD*AC + 0.0424*AC+ 0.174*FL). 109 
Where the head measurements were missing, the formula based on AC and FL was used: 110 
EFW = 10(1.304 + 0.05281*AC + 0.1938*FL - 0.004*AC*FL). Following delivery, the results of the research 111 
scans were un-blinded and their associations with outcome were assessed.  112 
 113 
Screening status in relation to EFW was classified on the basis of the last scan prior to birth 114 
(for universal ultrasonography this was the 36 week scan). Screen positive was defined as 115 
an EFW>90th percentile using an externally derived reference range(13, 14) (both selective 116 
and universal). Screen negative was defined as an EFW≤90th percentile (both selective and 117 
universal), or when no clinically indicated scan had been performed ≥34 weeks gestational 118 
age (selective only). Customised percentiles of EFW were also calculated using published 119 
methods,(15) but employing co-efficients from the most recent model (GROW v6.7.3_13 120 
[UK], Gestation Network [www.gestation.net]). The associations between population-based 121 
and customised EFW>90th percentile and neonatal morbidity were compared.  122 
 123 
Analysis of ultrasonic indicators of overgrowth was performed by comparing the association 124 
between an EFW>90th percentile and neonatal morbidity in the presence or absence of the 125 
given factor. HC:AC and AC:FL ratios were classified by the last measurement performed 126 
prior to birth. All measurements were quantified as gestational age adjusted z scores, to take 127 
into account variation in the exact timing of ultrasound scans (Supplementary Tables 1 & 2 in 128 
Sovio et al(9)). AC growth velocity (ACGV) was quantified as the difference in AC z score 129 
comparing the 36 week scan and the 20 week scan. For these three indices, deciles were 130 
generated using the distribution within the study cohort. The lowest decile of HC:AC and the 131 
highest deciles of AC:FL and AC growth velocity were defined as abnormal. No other growth 132 
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indices were studied to reduce the possibility of chance findings due to repeated hypothesis 133 
tests.  134 
 135 
Outcome data 136 
The outcome of the pregnancy was ascertained by individual review of all paper case 137 
records by research midwives, and by linkage of the research data to the hospital’s 138 
electronic databases of delivery (Protos, iSoft, Banbury, UK), biochemical tests (Meditech, 139 
Westwood MA, USA) and neonatal intensive care (Badgernet, Clevermed Ltd, Edinburgh, 140 
UK). The gold standard for LGA was birth weight >90th percentile for sex and gestational 141 
age, calculated using a UK reference.(16) Macrosomia was defined as birth weight >4000g 142 
and severe macrosomia was defined as birth weight >4500g. Neonatal morbidity was 143 
defined as ≥1 of the following: a 5 minute Apgar score less than 7, delivery with metabolic 144 
acidosis (defined as a cord blood pH <7.1 and a base deficit of >10mmol/L) or admission to 145 
the neonatal unit at term (defined as admission <48 hours after birth at ≥37 weeks 146 
gestational age and discharge ≥48 hours after admission). Severe adverse neonatal 147 
outcome was defined as term live birth associated with neonatal death, hypoxic ischemic 148 
encephalopathy, use of inotropes, mechanical ventilation, or severe metabolic acidosis 149 
(defined as a cord blood pH <7.0 and a base deficit of >12mmol/L). Shoulder dystocia and 150 
neonatal hypoglycaemia were documented in the electronic delivery record. Additional cases 151 
of diagnosed hypoglycaemia were obtained from the neonatal intensive care database, 152 
which was also used to identify cases of neonatal jaundice. These conditions were sub-153 
classified on the basis of whether they were associated with neonatal morbidity or severe 154 
adverse neonatal outcome, as defined above. 155 
 156 
Statistics 157 
Continuous variables were compared using a two-sample Wilcoxon rank-sum test and 158 
categorical variables were compared using the Pearson Chi-square test (with a trend test 159 
where appropriate) or Fisher’s exact test where numbers were small. Sensitivity and 160 
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specificity were compared using McNemar’s test, positive and negative predictive values 161 
were compared using weighted generalized score tests,(17) and likelihood ratios were 162 
compared using regression model based tests.(18) Analyses were repeated adjusting for 163 
pre-existing diabetes and gestational diabetes using exact logistic regression. Interactions 164 
between EFW and ultrasonic markers of overgrowth in their associations with neonatal 165 
morbidity were tested using the Mantel-Haenszel test or exact logistic regression, as 166 
appropriate. Conditional probabilities test was used to calculate p-values from the exact 167 
logistic regression(19) since the exact probabilities are analogous to the exact p-values 168 
obtained from a Fisher's exact test.(20) Statistical significance was assumed at P<0.05 (two 169 
sided). Analyses were performed using Stata version 14.1. and R version 3.0.2.   170 




In total, 4,512 (56%) women were recruited to the study and provided written informed 173 
consent.(9) We excluded women who withdrew from the study or defaulted from their 36 174 
week research scan (n=326), delivered before the 36 week scan (n=176) or had missing 175 
biometric measurements (n=12). We excluded further 127 women who were lost to follow-up 176 
or did not deliver in the Rosie Hospital and 5 women who had a stillbirth after their 36 week 177 
scan (Supplementary Figure 1). The study group for the present analysis consisted of 3,866 178 
women (86% of all recruited). A total of 1,354 of these women (35%) had a clinically 179 
indicated scan including biometry ≥34 wkGA (Table 1). Women having clinically indicated 180 
scans were more likely to be at extremes of maternal age, to have discontinued education 181 
earlier in life, to have a body mass index >30, to have had previous miscarriages, and to 182 
have pre-existing diabetes or to develop gestational diabetes than the women who did not 183 
have clinically indicated scans. The average birth weight of their infants was lower, and they 184 
had a greater proportion of LGA infants, births < 40 wkGA, induced labors and pre-labor 185 
cesarean deliveries.  186 
 187 
A total of 177 (4.6%) infants had a birth weight >90th percentile. The last clinically indicated 188 
scan (selective) before birth recorded an EFW>90th percentile in 47 of these cases yielding a 189 
sensitivity of 27%. The research 36 week ultrasound scan (universal) recorded an EFW of 190 
>90th percentile in 67 of these cases yielding a sensitivity of 38% (67/177). The specificity 191 
was high for both approaches, but was slightly higher for selective compared with universal 192 
ultrasonography (99% versus 97%, respectively). Screening summary statistics for universal 193 
and selective ultrasonography are presented (Table 2). The area under the receiver 194 
operating characteristic curve for LGA detected by selective ultrasonography was 0.72 and 195 
for universal ultrasonography was 0.87 (Figure 1).  196 
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There was no evidence for association between an EFW >90th percentile from universal 197 
ultrasound and the risk of neonatal morbidity using either population based or customised 198 
reference percentiles (Table 3, raw data (n/N) are shown in Supplementary Table 1). The 199 
association between an EFW >90th percentile and the risk of neonatal morbidity was then 200 
assessed in relation to three previously described indices of overgrowth (Figure 2). The only 201 
measurement where there was evidence for an interaction was with increased (i.e. top 202 
decile) of AC growth velocity. An interaction was observed for both any morbidity (P=0.08) 203 
and severe adverse neonatal outcome (P=0.03). There was no clear indication of an 204 
increased overall risk of adverse neonatal outcome where the EFW was >90th and the ACGV 205 
was not in the top decile, unless the baby was LGA at birth (Table 3). However, in the cases 206 
where universal ultrasonography demonstrated an LGA fetus with increased ACGV, there 207 
was a doubling in the risk of any neonatal morbidity (relative risk 2.0, 95% CI 1.1 to 3.6, 208 
P=0.04) and greater than 6-fold risk of severe adverse neonatal outcome (relative risk 6.5, 209 
95% CI 2.0 to 21.1, P=0.01). When the outcome was confined to cases of neonatal morbidity 210 
where the baby was actually confirmed to be LGA, ultrasonic LGA was associated with a 10-211 
fold risk and the combination of LGA and top decile of ACGV was associated with a greater 212 
than 20-fold risk. The associations remained very similar after adjustments for pre-existing 213 
diabetes and gestational diabetes (Table 3).  214 
 215 
All analyses of ACGV were repeated using AC growth charts generated by the Fetal Growth 216 
Longitudinal Study component of the INTERGROWTH-21st Project,(21) an international 217 
consortium which constructed fetal growth standards using methods recommended by the 218 
WHO and the associations were virtually unchanged (Supplementary Table 2). None of the 219 
indices of overgrowth were associated with adverse outcome when the EFW was ≤90th 220 
percentile (Supplementary Table 3). In addition, screening summary statistics for universal 221 
ultrasonography for detecting macrosomia and severe macrosomia are presented 222 
(Supplementary Table 4). The area under the receiver operating characteristic curve for 223 
macrosomia was 0.83 (95%CI 0.81-0.85) and for severe macrosomia was 0.87 (95%CI 0.82-224 
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0.91). Among infants who had EFW >90th percentile in the universal ultrasound, 41% were 225 
delivered through intrapartum emergency caesarean section, whereas the proportion was 226 
17% when the EFW was ≤90th percentile (risk ratio 2.50 [95%CI 2.08 to 3.00]). Finally, there 227 
were no significant associations between ultrasonic suspicion of LGA, with or without 228 
increased ACGV, and the risk of shoulder dystocia (Table 4). The risk of neonatal 229 
hypoglycaemia was elevated when there was a combination of ultrasonic suspicion of LGA 230 
and increased ACGV (Supplementary Table 5) but the risk of jaundice was not elevated in 231 
any of the groups (Supplementary Table 6).  232 




The main findings of the current analysis were (i) that universal ultrasonography increased 235 
the detection of LGA infants from 27% to 38%, and (ii) that the only ultrasonic marker of fetal 236 
overgrowth that discriminated between LGA infants at increased risk of neonatal 237 
complications was the ACGV. LGA fetuses with a normal ACGV were not at increased risk 238 
of adverse outcome. However, LGA fetuses with accelerated ACGV were at increased risk 239 
of adverse neonatal outcome, including severe outcome.  240 
 241 
The present study has immediate implications for obstetric care. Many women have late 242 
pregnancy ultrasound with indications including prior risk factors and acquired pregnancy 243 
complications. LGA will be diagnosed in a proportion of these women. The current study 244 
indicates that, where this diagnosis is made, assessment of the ACGV helps assess the risk 245 
of associated complications. Diagnosis of LGA with normal ACGV did not appear to be 246 
associated with an increased risk of adverse neonatal outcome, whereas diagnosis of LGA 247 
with accelerated ACGV was significantly associated with an increased risk of any neonatal 248 
morbidity. This diagnostic combination was also significantly associated with severe adverse 249 
neonatal outcome but as the latter occurred in only 0.6% of all infants, the association has 250 
relatively wide confidence intervals (Figure 2b). Importantly, we used the AC measurement 251 
at the routine 20 week anomaly scan as the baseline measurement. This means that an 252 
assessment of growth velocity can be made even when a woman has had only a single scan 253 
in late pregnancy.  254 
 255 
The aim of this study was to assess the diagnostic effectiveness of late pregnancy scanning, 256 
hence we have excluded women that delivered before reaching late pregnancy. An 257 
interesting finding, which we also noted in our previous study on universal screening for 258 
small-for-gestational age infants,(9) was that the positive likelihood ratio was significantly 259 
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higher in the selective screening group. We believe that the result from selective screening 260 
probably reflects both the indication for doing the scan and the scan result itself, whereas the 261 
likelihood ratio from the universal screening reflects simply the scan result.  262 
 263 
Interestingly, the association between ultrasonic diagnosis of fetal overgrowth and neonatal 264 
morbidity was not mediated through associations with shoulder dystocia. No combination of 265 
LGA or ACGV was significantly associated with shoulder dystocia, considering either any 266 
documentation of the condition at the time of delivery, or shoulder dystocia associated with 267 
neonatal morbidity. Therefore, the association between fetal overgrowth and adverse 268 
neonatal outcome was mediated by other causes. This is consistent with the view that 269 
macrosomia associated with pathological fetal overgrowth has multiple adverse effects on 270 
the fetus, in addition to predisposing to birth injuries.(22) Serious shoulder dystocia only 271 
affected 1.6 per 1,000 pregnancies in the current study and this analysis was underpowered 272 
to address this outcome. A recent randomised controlled trial demonstrated improved 273 
outcome following induction of labor at 37-38 wkGA for suspected macrosomia. That study 274 
employed women who had ultrasound scans for clinically suspected macrosomia and used 275 
an EFW threshold of >95th percentile, and these features may explain the high rates of 276 
shoulder dystocia and severe morbidity. However, the current study demonstrates that these 277 
findings should be applied cautiously to women who are suspected to have a LGA fetus in 278 
the absence of clinically suspected macrosomia, and that macrosomia may be associated 279 
with adverse neonatal outcome through mechanisms other than shoulder dystocia. Our 280 
findings are also consistent with a preliminary report from another prospective cohort study 281 
using blinded ultrasonic EFW in nulliparous women, which showed no association with 282 
shoulder dystocia.(23) Finally, this study was underpowered to address the association 283 
between LGA and specific neonatal outcomes such as metabolic acidosis or low Apgar 284 
score as these were present in <1% of the cohort.  285 
 286 
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We found no evidence to suggest that use of a customised EFW resulted in a stronger 287 
association between LGA and adverse neonatal outcome although the present study was 288 
underpowered to address serious shoulder dystocia as an outcome. The aim of ultrasonic 289 
assessment of growth is to differentiate pathological LGA from healthy LGA. Customisation 290 
of EFW attempts to achieve this by correcting the estimated fetal size for the maternal 291 
characteristics. Assessment of the ACGV uses the fetal AC in earlier pregnancy as the 292 
reference for later measurements, rather than using a reference modified for maternal 293 
characteristics. We used the highest decile to describe abnormal growth velocity since it is 294 
easy to use and interpret. The disadvantages are that it is specific to our cohort in its use of 295 
data-driven cut-off points, and, similarly to any categorisation of a continuous trait, assumes 296 
an unrealistic step-function of risk and within-group homogeneity.(24) In both the current 297 
analysis and our previous analysis of SGA and fetal growth restriction, we found that the 298 
ACGV was better than customisation in identifying fetuses in the extremes of the distribution 299 
of EFW which were at increased risk of neonatal complications. However, we did find that 300 
the estimated association between customised EFW and shoulder dystocia was stronger, 301 
although statistically non-significant. In that case, the outcome is determined by the 302 
interaction between the size of the fetus and the size of the mother, and it is plausible that 303 
customisation might perform better in that situation. We also used the INTERGROWTH-21st 304 
Project reference centiles which performed similarly to population and customised centiles.  305 
 306 
In conclusion, the present study found that universal ultrasonographic fetal biometry 307 
increases the detection of LGA infants and combined with ACGV stratifies infants to those 308 
who are at increased risk of adverse neonatal outcome. The immediate clinical implication of 309 
the study is that once the fetus is diagnosed LGA, assessment of the ACGV gives further 310 
information on the risk of associated complications which helps in planning obstetric care in 311 
late pregnancy. The current study is also the first to provide level 1 evidence of the 312 
diagnostic effectiveness of universal ultrasound to detect LGA. However, a randomized 313 
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controlled trial would be required prior to clinical implementation of screening and 314 
intervention.  315 
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Legends for figures. 337 
 338 
Figure 1. Receiver operating characteristic (ROC) curves for screening for an LGA infant 339 
using ultrasonic estimated fetal weight (EFW), comparing selective ultrasonography (dashed 340 
line), and universal ultrasonography (solid line). When the results of selective 341 
ultrasonography were analysed, 65% (2512/3866) of women did not have a clinically 342 
indicated scan at or after 34 weeks gestation. In this group, EFW centile was imputed using 343 
a sex-specific population median (46.30 in males, 38.93 in females). Areas under the ROC 344 
curves (95% confidence interval) are 0.72 (0.68-0.76) for selective scan and 0.87 (0.85-0.90) 345 
for universal scan. P<0.0001 for the comparison of the two approaches.  346 
 347 
Figure 2. Stratified analyses of perinatal outcome associated with diagnosis of large for 348 
gestational age (LGA) using universal ultrasonography in relation to ultrasonographic 349 
indicators of fetal overgrowth.  A. Any neonatal morbidity. B. Severe adverse neonatal 350 
outcome. The three previously described indices of fetal overgrowth were classified as the 351 
extreme decile associated with fetal overgrowth (highest or lowest, as appropriate) 352 
compared with the other nine deciles in the cohort. Z score cut-off point is 1.4285 for the 353 
highest decile of ACGV, 1.2789 for the highest decile of AC:FL ratio and -1.2484 for the 354 
lowest decile of HC:AC ratio. Points are relative risks of any neonatal morbidity (A) or odds 355 
ratios (B) associated with an ultrasonic diagnosis of a large for gestational age (LGA) infant 356 
at the 36 week scan. P values are from Mantel-Haenszel test of interaction (A) or from 357 
conditional probabilities test for interaction which is analogous to the Fisher's exact test (B). 358 
The upper confidence limit of the odds ratio is infinity for the highest decile of ACGV and the 359 
lowest decile of HC:AC ratio. The odds ratio axis has been truncated to 1000. AC, abdominal 360 
circumference; GV, growth velocity; FL, femur length; HC, head circumference.  361 
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Table 1. Characteristics of the study cohort (N=3,866).  
      
Characteristic No clinically 




indicated scan ≥34 
weeks 
(N=1354) 
P Value Overall baseline 
characteristics 
(N=3866) 
      
Maternal characteristics  
Age, years     




 20 to 24.9 350 (14%) 161 (12%) 511 (13%) 
 25 to 29.9 821 (33%) 371 (27%) 1192 (31%) 
 30 to 34.9 947 (38%) 488 (36%) 1435 (37%) 
 35 to 39.9 299 (12%) 222 (16%) 521 (13%) 
 ≥40 24 (1%) 47 (3%) 71 (2%) 
      
Age stopped FTE, years     
 <19 800 (32%) 480 (35%)  
0.03 
1280 (33%) 
 19 to 22 889 (35%) 454 (34%) 1343 (35%) 
 ≥23 756 (30%) 377 (28%) 1133 (29%) 
 Missing  
 
67 (3%) 43 (3%)  110 (3%) 
Deprivation quartile     
 1 (lowest) 611 (24%) 332 (24%)  
0.92 
943 (24%) 
 2 593 (24%) 324 (24%) 917 (24%) 
 3 602 (24%) 329 (24%) 931 (24%) 
 4 (highest) 592 (24%) 325 (24%) 917 (24%) 
 Missing  
 
114 (5%) 44 (3%)  158 (4%) 
Postcode area     




 Peripheral Cambridge 
city 
558 (22%) 322 (24%) 880 (23%) 
 Cambridgeshire, 
outside city 
605 (24%) 363 (27%) 968 (25%) 
 Outside 
Cambridgeshire 
502 (20%) 234 (17%) 736 (19%) 
 Missing  
 
72 (3%) 22 (2%)  94 (2%) 
White ethnicity 2336 (93%) 1261 (93%) 0.76 3597 (93%) 
 Missing  
 
45 (2%) 19 (1%)  64 (2%) 
Married 1713 (68%) 933 (69%) 0.65 2646 (68%) 
      
Smoker 115 (5%) 66 (5%) 0.67 181 (5%) 
      
Any alcohol consumption 123 (5%) 57 (4%) 0.33 180 (5%) 
 Missing  
 
1 (<1%) 0 (0%)  1 (<1%) 
BMI, kg/m2     




 25 to 29.9 713 (28%) 361 (27%) 1073 (28%) 
 30 to 34.9 238 (9%) 133 (10%) 371 (10%) 
 35 to 39.9 25 (1%) 79 (6%) 104 (3%) 
 ≥40 2 (<1%) 43 (3%) 45 (1%) 
 Missing  
 
0 (0%) 1 (<1%)  1 (<1%) 
≥1 previous miscarriage 223 (9%) 166 (12%) 0.001 389 (10%) 
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Diabetes     
 Type 1 or type 2 DM 0 (0%) 12 (1%)  
<0.0001 
12 (<1%) 
 Gestational DM 2 (<1%) 153 (11%) 155 (4%) 
     
Birth outcomes  
Birth weight, g 3485 (3190 to 3780) 3350 (3040 to 3680) <0.0001 3440 (3130 to 3750) 
 LGA (>90th)  93 (4%) 84 (6%) 0.0004 177 (5%) 
 Severe LGA (>97th) 12 (<1%) 25 (2%) <0.0001 37 (1%) 
 Macrosomia (>4000g) 303 (12%) 125 (9%) 0.007 428 (11%) 
 Severe macrosomia 
(>4500g) 
36 (1%) 22 (2%) 0.64 58 (2%) 
      
Gestational age, weeks 40.6 (39.7 to 41.3) 39.9 (38.9 to 40.9) <0.0001 40.4 (39.3 to 41.1) 





 37 77 (3%) 104 (8%) 181 (5%) 
 38 225 (9%) 217 (16%) 442 (11%) 
 39  460 (18%) 355 (26%) 815 (21%) 
 40 806 (32%) 322 (24%) 1128 (29%) 
 41 766 (30%) 271 (20%) 1037 (27%) 
 ≥ 42 160 (6%) 58 (4%) 218 (6%) 
      
Induction of labor 715 (29%) 532 (39%) <0.0001 1247 (32%) 
     
Mode of delivery     
 Spontaneous vaginal 1325 (53%) 557 (41%)  
<0.0001 
1882 (49%) 
 Assisted vaginal 649 (26%) 284 (21%) 933 (24%) 
 Intrapartum cesarean 458 (18%) 230 (17%) 688 (18%) 
 Pre-labor cesarean 76 (3%) 277 (20%) 353 (9%) 
 Missing  4 (<1%) 6 (<1%)  10 (<1%) 
      
 
Data are expressed as median (IQR) or n (%) as appropriate. P-values are for difference between 
groups calculated using the two-sample Wilcoxon rank-sum (Mann-Whitney) test for continuous 
variables and the Pearson Chi-square test for categorical variables, with trend test as appropriate. 
The missing category was not included in statistical tests. For fields where there is no category 
labelled "missing", data were 100% complete. 
Maternal age was defined as age at recruitment. All other maternal characteristics were defined by 
self-report at the 20 weeks questionnaire, from examination of the clinical case record, or linkage to 
the hospital’s electronic databases. Socio-economic status was quantified using the Index of Multiple 
Deprivation (IMD) 2007, which is based on census data from the area of the mother’s 
postcode.[Noble 2008, The English Indices of Deprivation 2007] The median (IQR) gestational age for 
the clinically indicated scan was 36.4 (36.0 to 37.9) weeks. 
Abbreviations: FTE denotes full time education, BMI denotes body mass index, DM denotes diabetes 
mellitus, LGA denotes large for gestational age.  
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Table 2. Comparison of diagnostic effectiveness of selective versus universal 
ultrasonography for detection of LGA infants. 
 Selective Universal P* 
True positive/ False positive 







Sensitivity (%) 27 (20-33) 38 (31-45) 0.005 
Specificity (%) 99 (98-99) 97 (96-97) <0.0001 
Positive likelihood ratio 20 (14-29) 11 (9-14) 0.002 
Negative likelihood ratio 0.74 (0.68-0.81) 0.64 (0.57-0.72) 0.01 
Positive predictive value (%) 49 (39-60) 35 (28-41) 0.002 
Negative predictive value (%) 97 (96-97) 97 (96-98) 0.01 
 
*Statistical comparison by DeLong, McNemar, or weighted generalised score tests, as appropriate. 
LGA denotes large for gestational age. LGA is defined as birth weight >90th percentile. Estimated fetal 
weight (EFW) measurement was taken from the last scan prior to birth. "Selective" reports the results 
of clinically indicated scans. If a woman did not have a clinically indicated scan at ≥34 weeks, she was 
defined as screen negative by selective ultrasonography. "Universal" reports the results of the 36 
week research scan. All values were calculated with EFW >90th percentile as screen positive. 95% 
confidence intervals are given in brackets.  
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Table 3. The relationship between estimated fetal weight (EFW) >90th percentile, abdominal circumference growth velocity (ACGV) and 
perinatal outcome using universal ultrasonography, total n=3,866. 
  Perinatal outcome 
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MULTIVARIABLE ANALYSIS            
  Adj OR 










































*Number of exposed cases = 0, therefore 95% confidence interval (CI) for relative risk (RR) is not defined.  
†Adjusted for pre-existing diabetes mellitus (DM) and gestational diabetes mellitus (GDM): odds ratio (OR) and 95% CI from exact logistic regression are 
given instead of RR.    
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All estimated fetal weights (EFWs) are based on population-based percentiles, unless stated otherwise. All RRs and ORs are referent to infants with an EFW 
of ≤90th percentile by population-based standards, except for the RRs for customised EFW >90th percentile, which are referent to infants with an EFW of the 
≤90th percentile by customised standards. Large for gestational age (LGA) is defined as birthweight of >90th percentile by population standards. Abdominal 
circumference growth velocity (ACGV) is based on the change in the gestational age adjusted Z score, comparing the result at the 20 week scan with the 36 
week scan. Z score cut-off point of the highest decile of ACGV is 1.4285. Any neonatal morbidity is a composite outcome—ie, one or more of these three 
outcomes: metabolic acidosis (defined as pH <7.1 and base deficit >10 mmol/L), 5 min Apgar score less than 7, and neonatal unit admission (defined as 
admission to the neonatal intensive care unit, the high dependency unit, or the special care baby unit). Severe adverse neonatal outcome is a composite 
outcome—ie, one or more of the following outcomes specified: neonatal death at term (not due to congenital anomaly), hypoxic ischemic encephalopathy at 
term, use of inotropes at term, mechanical ventilation at term, severe metabolic acidosis at term (defined as pH <7.0 and base deficit >12 mmol/L). 
Customized percentiles of EFW were calculated with the Gestation-Related Optimal Weight Customised Weight Centile Calculator (version 6.7 [UK]). P 
values for RRs are from Fisher’s exact test and p-values for ORs are from conditional probabilities test. All p-values are two-sided.   
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Table 4. The relationship between estimated fetal weight (EFW), abdominal circumference 
growth velocity (ACGV) and shoulder dystocia from universal ultrasonography, total 
n=3,866. 
  Outcome 
 
  Shoulder dystocia 
(n=62) 





TP/FP TN/FN LR+ 
  (95% CI) 
 
P 




          




2/192 3612/60 0.6 
(0.2-2.5) 
0.77 0/194 3666/6 0.0* 
-- 
>0.99 




10/352 3452/52 1.7 
(1.0-3.1) 
0.08 1/361 3499/5 1.8 
(0.3-10.7) 
0.45 




0/74 3715/62 0.0* 
-- 






6/380 3409/56 1.0 
(0.4-2.1) 
>0.99 1/385 3460/5 1.7 
(0.3-10.0) 
0.47 
 EFW>80th  +  
ACGV>1SD 
 
4/217 3572/58 1.1 
(0.4-2.9) 




*Number of exposed cases = 0, therefore 95% confidence interval (CI) for positive likelihood ratio 
(LR+) is not defined. All estimated fetal weights (EFWs) are based on population-based percentiles, 
unless stated otherwise. LR+s are referent to all other infants. Abdominal circumference growth 
velocity (ACGV) is based on the change in the gestational age adjusted Z score, comparing the result 
at the 20 week scan with the 36 week scan. Z score cut-off point of the highest decile of ACGV is 
1.4285. Any neonatal morbidity is a composite outcome—ie, one or more of these three outcomes: 
metabolic acidosis (defined as pH <7.1 and base deficit >10 mmol/L), 5 min Apgar score less than 7, 
and neonatal unit admission (defined as admission to the neonatal intensive care unit, the high 
dependency unit, or the special care baby unit). Customised percentiles of EFW were calculated with 
the Gestation-Related Optimal Weight Customised Weight Centile Calculator (version 6.7 [UK]). P 
values are from Fisher’s exact test. All p-values are two-sided. 
TP, true positive; FP, false positive; TN, true negative; FN, false negative. 
 
